New Launch26 Nov 2025, 12:29 pm
Zydus and RK Pharma Partner for Novel Oncology Supportive Care Product in US Market
AI Summary
Zydus Lifesciences Ltd. and RK Pharma Inc. have entered into an exclusive licensing and commercialization agreement for a novel sterile injectable 505(b)(2) oncology supportive care product for the US market. The product, developed under the 505(b)(2) pathway, is expected to be filed in 2026 and will provide a formulation intended to reduce dosing error and enhance compliance. The partnership is expected to tap into a significant commercial opportunity with an estimated total addressable market of 6.2 million units.
Key Highlights
- Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market.
- The product, developed under the 505(b)(2) pathway, is expected to provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals.
- RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US.
- The product targets a significant commercial opportunity in the U.S. market, with an estimated total addressable market (TAM) of 6.2 million units, according to IQVIA data MAT September 2025.
- The partnership reinforces Zydus' commitment to delivering high-quality, affordable medicines and improving patient care, and RK Pharma's advanced capabilities in formulation and manufacturing, particularly in specialized areas like sterile injectables and complex generics.